Recipharm, a leading contract development and manufacturing organisation (CDMO), has received recognition for its commitment to its French operations. The award “le Prix d’Excellence 2017 – Spécial Sciences de la vie” is presented by the Swedish Chamber of Commerce in France.
The award is to acknowledge examples of best practice in the Franco-Swedish business community. As part of the application process, Recipharm was assessed on its commercial success, profitability, technological innovation, quality and continued commitment to its operations in France.
Over the course of its 10-year history in France, Recipharm has increased its presence significantly and its operations in the country now account for 21% of the company’s overall sales, with 73% of those sales being exported across the globe.
Recipharm, which established its French operations in 2007, now operates four manufacturing facilities in the country, located in Fontaine-les-Dijon, Pessac, Monts and Kaysersberg. From these facilities, the CDMO provides a broad range of development and manufacturing services across areas including solid dosage formulation, sterile injectables manufacturing and blow-fill seal capabilities to a global customer base.
Jean-François Hilaire, Executive Vice President Strategy and Global Integration at Recipharm said: “We established our French operations ten years ago to cater for demand in Europe and offer easy market access to our customers. Since then we have acquired four sites and made substantial investments into our facilities, including an EUR 18 million investment in 2016 into our blow-fill seal capability in Kaysersberg to meet customer demand in the US, Turkey, Australia and Canada.”
“Our French facilities now serve over 50 of our customers worldwide, including a number of top 20 pharma firms, and employ over 20% of our staff. We have ongoing plans to grow our operations in the country and hope to see this positive trajectory continue for many years to come.”
Thomas Eldered, CEO at Recipharm added “I am honoured that Recipharm has been acknowledged for our decade-long commitment to France. We have been very pleased with the development of our business there and I would like to thank the Swedish Chamber of Commerce in France for recognising this.”
For more information about Recipharm’s facilities in France visit https://www.recipharm.com/locations .
Jean-Francois Hilaire, Executive Vice President Strategy & Global Integration, [email protected] , +33 695 447507
For media enquiries, please contact Kate Hindhaugh at ramarketing: [email protected] , +44 (0)191 222 1242, www.ramarketingpr.com , Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com .
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
Powered by WPeMatico